Pharvaris’ Post

👉 Exciting news in the fight against alcohol-use disorder! A recent study published reveals that Novo Nordisk's semaglutide, a GLP-1 receptor agonist, might significantly reduce the risk of AUD recurrence. The findings suggest that patients receiving semaglutide had up to a 56% lower risk of relapse. While more research is needed, this adds to the growing list of benefits from this remarkable drug. Check out the article for more details! ⬇ #HealthcareInnovation #AddictionRecovery #Semaglutide

New study uncovers how GPCRs, particularly the vasopressin V2 receptor (V2R), continue to signal from internalized compartments, highlighting the role of βarrestin (βarr) and Gβγ in non-canonical endosomal signaling. Discover how these mechanisms can pave the way for innovative therapeutic strategies. Check out the latest GPCR news in the Ecosystem today! You’ll need to register, but don’t worry, it’s Free! ➡️https://bit.ly/4d9yUQ3 #GPCR #DrGPCR

We are excited to share that Caitlyn Durgin is first author on this paper providing evidence of prominent differences in opioid response profiles that are present at opioid (hydromorphone) initiation. Developers of non-mu, opioid receptor agonist targets for treatment of pain, take note! Access the paper here, https://lnkd.in/eDWDEk-g #pain #opioid #clinicaldevelopment #data #drugdevelopment #personalizedmedicine 

“Mean body weight (kg) of participants taking #Semaglutide or a placebo over a two year observational trial." © 2022 Garvey et al. It’s clear Semaglutide, also known as #Ozempic and #Wegovy is a potent weight loss solution, but how does it truly work? Discover the effectiveness of this GLP-1 receptor agonist for weight loss and #Type2Diabetes in our most recent article, available here 🔽 https://bit.ly/47C40hi #ClinicalTrials #ObesityResearch

ScRNAseq analysis revealed the characteristics of CD4+ T cells in ACS, which could be therapeutic targets of ACS. @Emoto_Takuo https://lnkd.in/gScJKFA7

Reduction of Pannexin 1 rejuvenated senescent EPCs in therapeutic angiogenic potential through augmentation of IGF-1 https://lnkd.in/gyuN7e5S

Learn about the results of an open-label, long-term safety and tolerability analysis of adult patients in a phase 2/3 clinical trial of a CGRP receptor antagonist for the acute treatment of #migraine. These findings were published in the April edition of Cephalalgia.

Learn about the results of an open-label, long-term safety and tolerability analysis of adult patients in a phase 2/3 clinical trial of a CGRP receptor antagonist for the acute treatment of #migraine. These findings were published in the April edition of Cephalalgia. #PFEColleague

Sequential, multistep activation mechanism of metabotropic glutamate receptor subtype 5. Just out. https://lnkd.in/dCaR7J96

ENDO-TAGS :designed proteins that stimulate endocytosis of cell surface receptors for receptor lysosomal degredation by inducing receptor conformational change or dimerisation/ clustering. Many potential therapeutic possibilities here. #endocytosis #receptors #PROTACS #proteindesign #endolysosome #drugdesign https://lnkd.in/eTnB-Tk3